Clinical Trials Directory

Trials / Completed

CompletedNCT00027794

Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer

Radical Prostatectomy for Locally Advanced Prostate Cancer. A Feasibility Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC · Network
Sex
Male
Age
70 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Radical prostatectomy may be an effective treatment for locally advanced prostate cancer. PURPOSE: Phase II trial to study the effectiveness of radical prostatectomy in treating patients who have locally advanced prostate cancer.

Detailed description

OBJECTIVES: * Determine the success rate of radical prostatectomy in patients with locally advanced adenocarcinoma of the prostate. * Determine the serious toxic event rate of this surgery in these patients. * Determine the pN status of patients treated with this surgery. * Determine the percentage of patients found to have organ-confined tumors (pT2) after undergoing this surgery. * Determine the 2-year prostate-specific antigen-free survival rate of patients treated with this surgery. * Determine the surgical morbidity rates of patients treated with this surgery. OUTLINE: This is a multicenter study. Patients undergo limited pelvic lymphadenectomy and then radical retropubic prostatectomy. Patients who are found to have pN-positive disease receive further treatment according to the investigator's discretion. Patients with pN0 disease are followed every 3 months for 1 year and then every 4 months for 1 year. PROJECTED ACCRUAL: A total of 32-74 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
PROCEDUREconventional surgery

Timeline

Start date
2001-09-01
Primary completion
2005-01-01
First posted
2003-01-27
Last updated
2012-09-24

Locations

5 sites across 3 countries: Belgium, Italy, Slovakia

Source: ClinicalTrials.gov record NCT00027794. Inclusion in this directory is not an endorsement.